USA flag logo/image

An Official Website of the United States Government

THERAPEUTIC CLEARANCE OF COMPLEMENT FRAGMENT C5A

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
8033
Program Year/Program:
1988 / SBIR
Agency Tracking Number:
8033
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Synergen Inc
1885 33rd St Boulder, CO 80301
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1988
Title: THERAPEUTIC CLEARANCE OF COMPLEMENT FRAGMENT C5A
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

THE OVERALL GOAL OF THE PROPOSED RESEARCH IS TO PROVIDE A SPECIFIC, PRACTICAL MEANS FOR INACTIVATING C5A IN PATIENTS AT RISK OF ADULT RESPIRATORY DISTRESS SYNDROME (ARDS). C5A IS A KEY CONTRIBUTORY, POSSIBLY NECESSARY FACTOR IN THE PATHOLOGICAL COURSE OF ARDS. THE PROTEINS CAPABLE OF INACTIVATING C5A NOTED IN THE LITERATURE ARE POORLY CHARACTERIZED. SYNERGEN'S SCIENTISTS HAVE SELECTED ONE OF THESE PROTEINS TO ISOLATE FROM HUMAN TISSUE, THEN CHARACTERIZE ITS MODE OF ACTION. AN ASSAY BASED ON THIS BIOLOGICAL ACTIVITY WILL BE USED TO PURIFY, CHARACTERIZE, CLONE AND EXPRESS THE PROTEIN BY RECOMBINANT DNA TECHNOLOGIES. BY REDUCING THE ACTION OF C5A IN PATIENTS AT RISK FOR ARDS, WE EXPECT THAT THE PROTEIN WILL PROVIDE A USEFUL THERAPEUTIC AGENT FOR PREVENTION OR AMELIORATION OF THE PATHOLOGY.

Principal Investigator:


0

Business Contact:

Small Business Information at Submission:

Synergen Inc
1885 33rd St Boulder, CO 80301

EIN/Tax ID:
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No